TC
REGN icon

Truvestments Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Truvestments Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.1K Hold
105
– – 0.01% 424
2025
Q4 		$81K Buy
105
+53
+102% +$36K 0.01% 372
2025
Q3 		$29.3K Buy
52
+10
+24% +$5.65K 0.01% 522
2025
Q2 		$22.1K Buy
42
+26
+163% +$14.5K ﹤0.01% 519
2025
Q1 		$10.1K Sell
16
-26
-62% -$17.9K ﹤0.01% 654
2024
Q4 		$29.9K Buy
42
+5
+14% +$4.2K 0.01% 446
2024
Q3 		$38.9K Buy
+37
New +$41.2K 0.01% 392
2024
Q2 		– Sell
-8
Closed -$7.7K – 577
2024
Q1 		$7.7K Hold
8
– – ﹤0.01% 515
2023
Q4 		$7.03K Hold
8
– – ﹤0.01% 552
2023
Q3 		$6.58K Hold
8
– – ﹤0.01% 483
2023
Q2 		$5.75K Hold
8
– – ﹤0.01% 513
2023
Q1 		$6.57K Buy
8
+5
+167% +$3.77K ﹤0.01% 476
2022
Q4 		$2.16K Hold
3
– – ﹤0.01% 713
2022
Q3 		$2K Hold
3
– – ﹤0.01% 567
2022
Q2 		$2K Buy
+3
New +$1.95K ﹤0.01% 573

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Truvestments Capital's REGN Position: Q1 2026 in Review

Truvestments Capital held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 105 shares worth $81.1K. The position accounts for 0.01% of the portfolio, ranked #424.

Truvestments Capital first reported a position in REGN in Q2 2022 and has held it in 15 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Truvestments Capital held 105 shares of Regeneron Pharmaceuticals worth $81.1K as of Q1 2026.
  • Truvestments Capital left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #424 holding.
  • Truvestments Capital first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.